Panel Discussion: Advanced drug delivery: From oral to injectables and beyond

Panellists in this video:
• Dr Manikandan R, Sr VP, Granules India (Moderator)
• Dr Rakesh Bhasin, Head-Generic Formulations R&D, Biocon Pharma
• Mr Girish Achliya, CSO, Novapharm Healthcare
• Dr Ganeshchandra Sonavane, CSO, Umedica Laboratories
• Ms Debjani Singh, VP – Formulation & Development, Zydus Lifesciences
• Dr Sandhya Shenoy, VP – Formulation R&D, MSN Laboratories
• Dr Abhay Joshi, VP – Formulation Development, Dr. Reddy’s Laboratories
• Dr Dinesh Shinde, AVP & Head; Formulation Development and Tech Transfer, Wockhardt
• Ms Preeti Raut, Technical Consultant, Cipla

Key Highlights:
[1] Patient-centricity is the new innovation benchmark, with convenience and improved treatment experience driving formulation development.

[2] Reformulating existing drugs into advanced delivery systems (injectables, liposomes, nanoparticles, nanoemulsions) offers faster innovation than developing new chemical entities.

[3] Advanced drug delivery can improve efficacy and safety, as seen with nanoparticle-based formulations that reduce toxicity and optimize dosing.

[4] Long-acting formulations are gaining momentum, moving from daily dosing to monthly, quarterly, and even longer-duration therapies.

[5] Regulators are increasingly collaborative, enabling innovation through scientific dialogue, risk-based assessment, and early engagement.

[6] Technology adoption must remain patient-driven, focusing on solving real-world adherence, stability, and delivery challenges.

[7] Emerging platforms such as nanoparticles, micro-needle systems, depot injections, and device-drug combinations are reshaping the future of drug delivery.

[8] AI is accelerating formulation development by reducing experimentation, optimising design, and improving development efficiency.

[9] Overcoming biological, manufacturing, and regulatory barriers requires integrated expertise, supported by specialised technologies, CRO partnerships, and robust quality controls.